PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants. / HEBON Investigators.

I: npj Breast Cancer, Bind 9, Nr. 1, 37, 2023.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

HEBON Investigators 2023, 'PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants', npj Breast Cancer, bind 9, nr. 1, 37. https://doi.org/10.1038/s41523-023-00546-x

APA

HEBON Investigators (2023). PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants. npj Breast Cancer, 9(1), [37]. https://doi.org/10.1038/s41523-023-00546-x

Vancouver

HEBON Investigators. PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants. npj Breast Cancer. 2023;9(1). 37. https://doi.org/10.1038/s41523-023-00546-x

Author

HEBON Investigators. / PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants. I: npj Breast Cancer. 2023 ; Bind 9, Nr. 1.

Bibtex

@article{df1d5682faaa479e9ba9a78727ae34ab,
title = "PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants",
abstract = "We assessed the PREDICT v 2.2 for prognosis of breast cancer patients with pathogenic germline BRCA1 and BRCA2 variants, using follow-up data from 5453 BRCA1/2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and the Breast Cancer Association Consortium (BCAC). PREDICT for estrogen receptor (ER)-negative breast cancer had modest discrimination for BRCA1 carrier patients overall (Gonen & Heller unbiased concordance 0.65 in CIMBA, 0.64 in BCAC), but it distinguished clearly the high-mortality group from lower risk categories. In an analysis of low to high risk categories by PREDICT score percentiles, the observed mortality was consistently lower than the expected mortality, but the confidence intervals always included the calibration slope. Altogether, our results encourage the use of the PREDICT ER-negative model in management of breast cancer patients with germline BRCA1 variants. For the PREDICT ER-positive model, the discrimination was slightly lower in BRCA2 variant carriers (concordance 0.60 in CIMBA, 0.65 in BCAC). Especially, inclusion of the tumor grade distorted the prognostic estimates. The breast cancer mortality of BRCA2 carriers was underestimated at the low end of the PREDICT score distribution, whereas at the high end, the mortality was overestimated. These data suggest that BRCA2 status should also be taken into consideration with tumor characteristics, when estimating the prognosis of ER-positive breast cancer patients.",
keywords = "MODEL PREDICT, SURVIVAL, VALIDATION, ADJUVANT, OVARIAN, WOMEN, TOOL",
author = "Taru Muranen and Anna Morra and Khan, {Sofia R.} and Barnes, {Daniel K.} and Manjeet Bolla and Joe Dennis and Renske Keeman and Leslie, {Goska T.} and Michael Parsons and Wang, {Qin U.} and Thomas Ahearn and Aittomaeki, {Kristiina L.} and Andrulis, {Irene K.} and Banu Arun and Sabine Behrens and Bialkowska, {Katarzyna E.} and Bojesen, {Stig J.} and Nicola Camp and Jenny Chang-Claude and Kamila Czene and Devilee, {Peter M.} and Domchek, {Susan M.} and Alison Dunning and Christoph Engel and Evans, {D. Gareth} and Manuela Gago-Dominguez and Montserrat Garcia-Closas and Anne-Marie Gerdes and Gord Glendon and Pascal Guenel and Eric Hahnen and Ute Hamann and Hanson, {Helen J.} and Maartje Hooning and Reiner Hoppe and Louise Izatt and Jakubowska, {Anna A.} and James, {Paul N.} and Vessela Kristensen and Lalloo, {Fiona J.} and Geoffrey Lindeman and Arto Mannermaa and Margolin, {Sara L.} and Neuhausen, {Susan G.} and William Newman and Paolo Peterlongo and Kelly-Anne Phillips and Pujana, {Miquel Angel} and Johanna Rantala and Karina Ronlund and {HEBON Investigators}",
year = "2023",
doi = "10.1038/s41523-023-00546-x",
language = "English",
volume = "9",
journal = "npj Breast Cancer",
issn = "2374-4677",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants

AU - Muranen, Taru

AU - Morra, Anna

AU - Khan, Sofia R.

AU - Barnes, Daniel K.

AU - Bolla, Manjeet

AU - Dennis, Joe

AU - Keeman, Renske

AU - Leslie, Goska T.

AU - Parsons, Michael

AU - Wang, Qin U.

AU - Ahearn, Thomas

AU - Aittomaeki, Kristiina L.

AU - Andrulis, Irene K.

AU - Arun, Banu

AU - Behrens, Sabine

AU - Bialkowska, Katarzyna E.

AU - Bojesen, Stig J.

AU - Camp, Nicola

AU - Chang-Claude, Jenny

AU - Czene, Kamila

AU - Devilee, Peter M.

AU - Domchek, Susan M.

AU - Dunning, Alison

AU - Engel, Christoph

AU - Evans, D. Gareth

AU - Gago-Dominguez, Manuela

AU - Garcia-Closas, Montserrat

AU - Gerdes, Anne-Marie

AU - Glendon, Gord

AU - Guenel, Pascal

AU - Hahnen, Eric

AU - Hamann, Ute

AU - Hanson, Helen J.

AU - Hooning, Maartje

AU - Hoppe, Reiner

AU - Izatt, Louise

AU - Jakubowska, Anna A.

AU - James, Paul N.

AU - Kristensen, Vessela

AU - Lalloo, Fiona J.

AU - Lindeman, Geoffrey

AU - Mannermaa, Arto

AU - Margolin, Sara L.

AU - Neuhausen, Susan G.

AU - Newman, William

AU - Peterlongo, Paolo

AU - Phillips, Kelly-Anne

AU - Pujana, Miquel Angel

AU - Rantala, Johanna

AU - Ronlund, Karina

AU - HEBON Investigators

PY - 2023

Y1 - 2023

N2 - We assessed the PREDICT v 2.2 for prognosis of breast cancer patients with pathogenic germline BRCA1 and BRCA2 variants, using follow-up data from 5453 BRCA1/2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and the Breast Cancer Association Consortium (BCAC). PREDICT for estrogen receptor (ER)-negative breast cancer had modest discrimination for BRCA1 carrier patients overall (Gonen & Heller unbiased concordance 0.65 in CIMBA, 0.64 in BCAC), but it distinguished clearly the high-mortality group from lower risk categories. In an analysis of low to high risk categories by PREDICT score percentiles, the observed mortality was consistently lower than the expected mortality, but the confidence intervals always included the calibration slope. Altogether, our results encourage the use of the PREDICT ER-negative model in management of breast cancer patients with germline BRCA1 variants. For the PREDICT ER-positive model, the discrimination was slightly lower in BRCA2 variant carriers (concordance 0.60 in CIMBA, 0.65 in BCAC). Especially, inclusion of the tumor grade distorted the prognostic estimates. The breast cancer mortality of BRCA2 carriers was underestimated at the low end of the PREDICT score distribution, whereas at the high end, the mortality was overestimated. These data suggest that BRCA2 status should also be taken into consideration with tumor characteristics, when estimating the prognosis of ER-positive breast cancer patients.

AB - We assessed the PREDICT v 2.2 for prognosis of breast cancer patients with pathogenic germline BRCA1 and BRCA2 variants, using follow-up data from 5453 BRCA1/2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and the Breast Cancer Association Consortium (BCAC). PREDICT for estrogen receptor (ER)-negative breast cancer had modest discrimination for BRCA1 carrier patients overall (Gonen & Heller unbiased concordance 0.65 in CIMBA, 0.64 in BCAC), but it distinguished clearly the high-mortality group from lower risk categories. In an analysis of low to high risk categories by PREDICT score percentiles, the observed mortality was consistently lower than the expected mortality, but the confidence intervals always included the calibration slope. Altogether, our results encourage the use of the PREDICT ER-negative model in management of breast cancer patients with germline BRCA1 variants. For the PREDICT ER-positive model, the discrimination was slightly lower in BRCA2 variant carriers (concordance 0.60 in CIMBA, 0.65 in BCAC). Especially, inclusion of the tumor grade distorted the prognostic estimates. The breast cancer mortality of BRCA2 carriers was underestimated at the low end of the PREDICT score distribution, whereas at the high end, the mortality was overestimated. These data suggest that BRCA2 status should also be taken into consideration with tumor characteristics, when estimating the prognosis of ER-positive breast cancer patients.

KW - MODEL PREDICT

KW - SURVIVAL

KW - VALIDATION

KW - ADJUVANT

KW - OVARIAN

KW - WOMEN

KW - TOOL

U2 - 10.1038/s41523-023-00546-x

DO - 10.1038/s41523-023-00546-x

M3 - Journal article

C2 - 37173335

VL - 9

JO - npj Breast Cancer

JF - npj Breast Cancer

SN - 2374-4677

IS - 1

M1 - 37

ER -

ID: 347812897